ECSP16024798A - Nuevo compuesto para el tratamiento de hipoglicemia severa - Google Patents

Nuevo compuesto para el tratamiento de hipoglicemia severa

Info

Publication number
ECSP16024798A
ECSP16024798A ECIEPI201624798A ECPI201624798A ECSP16024798A EC SP16024798 A ECSP16024798 A EC SP16024798A EC IEPI201624798 A ECIEPI201624798 A EC IEPI201624798A EC PI201624798 A ECPI201624798 A EC PI201624798A EC SP16024798 A ECSP16024798 A EC SP16024798A
Authority
EC
Ecuador
Prior art keywords
treatment
new compound
severe hypoglycemia
hypoglycemia
severe
Prior art date
Application number
ECIEPI201624798A
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Robert Chadwick Cummins
Lili Guo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP16024798A publication Critical patent/ECSP16024798A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Removal Of Specific Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un nuevo compuesto útil en el tratamiento de hipoglicemia.
ECIEPI201624798A 2013-12-18 2016-06-16 Nuevo compuesto para el tratamiento de hipoglicemia severa ECSP16024798A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917597P 2013-12-18 2013-12-18

Publications (1)

Publication Number Publication Date
ECSP16024798A true ECSP16024798A (es) 2017-05-31

Family

ID=52278802

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201624798A ECSP16024798A (es) 2013-12-18 2016-06-16 Nuevo compuesto para el tratamiento de hipoglicemia severa

Country Status (27)

Country Link
US (1) US9695225B2 (es)
EP (1) EP3083668A1 (es)
JP (1) JP2017509584A (es)
KR (1) KR20160075825A (es)
CN (1) CN105814076A (es)
AP (1) AP2016009242A0 (es)
AR (1) AR098614A1 (es)
AU (1) AU2014366424B2 (es)
BR (1) BR112016012067A2 (es)
CA (1) CA2928985A1 (es)
CL (1) CL2016001472A1 (es)
CR (1) CR20160226A (es)
DO (1) DOP2016000096A (es)
EA (1) EA201690914A1 (es)
EC (1) ECSP16024798A (es)
GT (1) GT201600117A (es)
HK (1) HK1224304A1 (es)
IL (1) IL245400A0 (es)
MA (1) MA39109B1 (es)
MX (1) MX2016007982A (es)
NZ (1) NZ719463A (es)
PE (1) PE20160848A1 (es)
PH (1) PH12016501182A1 (es)
SG (1) SG11201604154SA (es)
TN (1) TN2016000181A1 (es)
TW (1) TW201609127A (es)
WO (1) WO2015094875A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CA3128922A1 (en) 2019-02-05 2020-08-13 Eli Lilly And Company Glucagon analog agonists and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE553124T1 (de) 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
JP6108659B2 (ja) 2008-06-17 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト
CN102088989B (zh) * 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2011143208A1 (en) * 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
WO2012088116A2 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
EP3434687B1 (en) * 2011-06-10 2021-03-10 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
JP6396211B2 (ja) 2011-07-04 2018-09-26 インペリアル・イノベイションズ・リミテッド 新規化合物及び摂食行動に対するそれらの効果
JP6311708B2 (ja) * 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ

Also Published As

Publication number Publication date
CL2016001472A1 (es) 2017-03-10
EP3083668A1 (en) 2016-10-26
TW201609127A (zh) 2016-03-16
AU2014366424B2 (en) 2017-02-16
MX2016007982A (es) 2016-09-09
GT201600117A (es) 2017-07-06
KR20160075825A (ko) 2016-06-29
IL245400A0 (en) 2016-06-30
MA39109A1 (fr) 2017-09-29
TN2016000181A1 (en) 2017-10-06
CA2928985A1 (en) 2015-06-25
DOP2016000096A (es) 2016-08-15
BR112016012067A2 (pt) 2017-09-26
SG11201604154SA (en) 2016-07-28
PE20160848A1 (es) 2016-09-10
US9695225B2 (en) 2017-07-04
JP2017509584A (ja) 2017-04-06
CR20160226A (es) 2016-07-12
EA201690914A1 (ru) 2016-09-30
CN105814076A (zh) 2016-07-27
AR098614A1 (es) 2016-06-01
MA39109B1 (fr) 2018-04-30
AU2014366424A1 (en) 2016-05-19
WO2015094875A1 (en) 2015-06-25
AP2016009242A0 (en) 2016-06-30
US20160311881A1 (en) 2016-10-27
HK1224304A1 (zh) 2017-08-18
PH12016501182A1 (en) 2016-07-25
NZ719463A (en) 2017-09-29

Similar Documents

Publication Publication Date Title
UY34654A (es) Inhibidores de la beta-secretasa
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
IN2013DE00266A (es)
AR097668A1 (es) Colorante-polímero
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
DOP2016000067A (es) Nuevo inhibidor de sglt1
CL2016000171A1 (es) Formulación de metaxalona.
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
BR112015021575A2 (pt) composição fungicida
IN2013MU03768A (es)
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия
CL2012000641S1 (es) Lavamanos.
TH127247B (th) องค์ประกอบสำหรับการปรับปรุงสภาพของผิวหนัง
TN2011000399A1 (fr) دراجة كهربائية ذات شحن الي
TN2011000372A1 (fr) جهاز مراقبة وتحكم في استهلاك المياه